Cantor's Irina Rivkind calls the upcoming FDA advisory committee review of Relistor (previous)...

|By:, SA News Editor

Cantor's Irina Rivkind calls the upcoming FDA advisory committee review of Relistor (previous) "another meaningful catalyst" for shares of Salix Pharmaceuticals (SLXP +4.1%) which are reiterated at Buy (PT $72). Approval of the drug may be "more manageable" than originally suspected, Rivkind adds.

Subscribe for full text news in your inbox